$VIRI FDA Approval On The Horizon?Up 230% since its Q4 earnings in March, Virios Therapeutics, Inc. (NASDAQ: VIRI) showed tremendous progress in its Q1 earnings in May. The company not only reported an EPS loss less than half of estimates, successfully reducing its cash burn by almost 60% QoQ, but reported significant progress in pr
